Researchers Identified CD70 as Lymphoma Driver
A 2026 study linked CD70 expression to immune evasion in mantle cell lymphoma, showing promise in preclinical models.
Updated on Sept. 29, 2026 in Cancer
Live Poll
Do you trust that early-stage laboratory medical research will result in successful patient treatments?
In 2026, researchers at Houston's MD Anderson Cancer Center discovered that CD70 expression drives immune evasion in mantle cell lymphoma. This finding led to the development of a CD70-targeting bispecific antibody that successfully eliminated resistant tumor cells in mouse models.
Why it matters
Mantle cell lymphoma tumor cells exploit the CD70-CD27 axis to escape immune surveillance by triggering T-cell exhaustion and apoptosis. Targeting this pathway offers a potential strategy for patients who develop resistance to standard BTK inhibitors and CAR T-cell therapies.
The study utilized single-cell RNA sequencing on 28 patient samples and flow cytometry on 11 primary specimens. In MAVER-1 mouse models, treatment with a bispecific antibody at doses of 10 and 100 μg/kg significantly inhibited tumor growth.
The players
MD Anderson Cancer Center
Located in Houston, this world-renowned institution is a leader in cancer research, patient care, and clinical trials.
The details
The research team engineered a CD70 × CD3 bispecific T-cell engager to block the CD70-CD27 signaling axis. This intervention reduced immunosuppressive markers like IL-10 and CD25 while increasing the production of tumor-killing granzyme B and interferon-γ.
Timeline
The preclinical findings were published in the journal Cancer Letters in 2026.
The Big Picture
This study follows a pattern of targeted immunotherapy development consistently produced by MD Anderson Cancer Center researchers. By focusing on overcoming T-cell exhaustion, the work aligns with modern efforts to bypass the resistance mechanisms that often render traditional CAR T-cell therapies ineffective.
While this research offers a future pathway for patients who fail standard lymphoma treatments, it remains at the preclinical stage. Patients should consult with their oncologists about currently available clinical trials that address resistance to BTK inhibitors and cellular therapies.
The takeaway
This study highlights the critical role of CD70 in immune evasion for treatment-resistant lymphoma cases. Future developments will focus on adapting these lab-tested bispecific antibodies for use in human immune-competent models.
Further reading
For more information on current treatment trends, visit the Cancer section.
More information
Read the complete Cancer Letters scientific study article for full technical details.
Source note: This article includes information reported by Ajmc.
Live Poll
Do you trust that early-stage laboratory medical research will result in successful patient treatments?
